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Introduction
Conclusions
Materials & Methods
Frequency of ICDs. Cross-sectional study
3090 PD patients under treatment >1year
Evaluation of pathological gambling, compulsive sexual 
behavior, compulsive buying and binge-eating disorder
Radioligand binding assays 
[3H]pramipexole and [3H]spiperone
Localization of the D3 dopamine receptor
In situ hybridization histochemistry 
Human D3 receptor cDNA 
Nissl staining 
Results
Aims
To find results that depict the percentage of patients who develop
Impulse Control Disorders, which of them were pramipexole-treated
patients and which are the most frequent ICDs.
To find results that determine the binding affinity of pramipexole to the
D3 receptor, in comparison to other dopamine agonists and other
receptors.
To find results that demonstrate the localization of the D3 dopamine
receptor to limbic areas of the brain.
% Hybridization signal (dpm/mg)
D3 receptor mRNA expression
420/3090 patients (13.6%) diagnosed with ICD.
83% of ICD patients under treatment with a DA.
17.1% of the patients taking a dopamine agonist
developed ICDs.
All types of ICDs are more frequent in dopamine
agonist-treated patients.
>1 ICD
No ICD
1 ICD
3.9%
ICD diagnosis in overall patients
DA treatmentICD patients
DA
No DA
ICD
No ICD
Dissociation constant D2L D3
KH (nM) 2.07±0.32 0.49±0.09
KL (nM) 139±32 2.78±0.45
KGppNHp (nM) 701±49 2.4±0.09
1. Competition assay using [3H]spiperone
2. Saturation assay using [3H]pramipexole
KD (nM) Bmax (pmol/mg)
D2L 1.26±0.25 0.70±0.22
D2S 0.96±0.13 0.58±0.06
D3 0.22±0.03
2.27±0.56
3.00±1.00
5.30±0.60
3. Indirect competition assay using 
↓[3H]pramipexole 
Ki (nM) D2L D2S D3
Pramipexole 3.9±0.2 3.3±0.3 0.5±0.1
Bromocriptine 2.5±0.4 4.8±0.8 12.2±1.7
Quinpirole 1.8±0.3 1.5±0.1 0.96±0.03
1. Pramipexole has a clear preference for the binding to
D3, when compared to one of the isoforms of the D2
receptor.
2. Two populations of binding sites with significantly
different affinities at the D3 receptor.
D3Bmax > D2Bmax
D2Kd ≈ 5.7 D3Kd(high)
3. D2Ki ≈ 7D3Kio High selectivity of pramipexole for D3
Pramipexole has the greatest binding affinity at D3, when
compared to other DAs
D3 more binding capacity 
and more affinity  
o
120 patients ≥ 2 ICD  ,  300 = 1 ICD
Parkinson Disease (PD) is a progressive neurodegeneration
that causes motor impairment. This results from the death of
dopaminergic neurons and the consequent depletion of
dopamine in the striatum.
Pramipexole is effective and alleviates the motor symptoms of PD but it has been associated with the
development of Impulse Control Disorders (ICDs). These comprise several psychiatric disorders
characterized by impulsivity, failure to resist temptations and inability to learn from negative outcomes.
Dopamine replacement therapies include levodopa and dopamine agonists (DAs). The latter are
competent and commonly prescribed drugs; Pramipexole is one of them.
17.1%
[1]
[2] [3] [4]
Acc
Pu
CN
Abbreviations. IC: islands of Calleja,  Acc: nucleus accumbens, CN: caudate 
nucleus, Pu: putamen, MB: mammillary body, Dg: dentate gyrus.  [4]
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↑↑↑D3 expression in areas that are part of or associated
with the limbic system.
↓ D3 expression in areas related to motor function.
Dual localization o D3 involved in both behavioral and
motor functions
Pramipexole
D2
D3
GPi Thalamocortical 
motor pathwaysX
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system ICD
PD 
alleviation
There is a clear association between DA treatment and 
ICD. This must be recognized as early as possible due to 
adverse personal and financial consequences.
Before starting a pramipexole treatment:
- Consider risk factors (early PD onset, novelty 
seeking, hypomania, impaired planning, family 
history of alcohol abuse). [5]
- Evaluate risk/benefit ratio.
- Adjust dose and therapy to each case.
If ICD develop: slowly reduce DA 
dose or switch to different DA with
lower affinity for the D3 receptor 
Future: elucidate the exact molecular mechanism responsible for the convergence of PD and 
ICD, as it is not clear yet. 
Further functional imaging studies and genome wide association studies. [6]
